4Basebio SE (4basebio UK Societas) on January 22, 2021 announced its intention to list on London's junior AIM market. "It is the intention of the company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use," said 4basebio UK. According to 4basebio UK: "This is the foundation for building the company's synthetic DNA manufacturing business which [4basebio AG] transferred to the company along with funding to continue the company's development and investment".